Study Identifies Pathway to Start of Joint Disease

Published Online: Saturday, May 1, 2004

British researchers are confident that they have found a way to block a molecular mechanism that activates arthritis, and they believe that the discovery may lead to new drugs for the disease. Using cultured cartilage cells, the researchers found that blocking the enzyme protein kinase R halted the production of enzymes that break down the connective tissue and allow proteoglycan to be lost.

"We found that treating cartilage cells with tumor necrosis factor-alpha (TNF-alpha) and C2-ceramide stimulated the arthritic process by a number of mechanisms," said lead investigator Sophie Gilbert, PhD. In particular, the scientists witnessed an increase in the release of matrix metalloproteinase (MMP-1 and -9), 2 enzymes involved in arthritis. Furthermore, an increased loss of proteoglycans was noted when cartilage cells were treated with TNF-alpha and C2-ceramide, as well as an increased cartilage cell death, according to the researchers. (These findings were published recently in Arthritis Research & Therapy.)

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues